ABSTRACT
Nanotechnology has led to the development of numerous new systems for drug delivery into the target tissue, as well as novel methods that may be useful in the treatment of liver fibrosis. Inorganic and organic nanoparticles (NPs) are currently used in medical investigations and in the treatment of liver diseases, with adverse reactions observed in some cases. A revised treatment procedure involving NPs is necessary to develop future drug delivery systems having minimal noxious effects on the hepatic cells that take up and metabolize these particles in a different manner, in order to find the medication that is capable of blocking and even reversing fibrosis in an inflamed liver. In addition, the administered medication should not induce systemic responses against the NPs used in the treatment.
